150 related articles for article (PubMed ID: 35451413)
1. Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation: A protocol for systematic review and meta-analysis.
Li H; Liang Y; Song X; Liu-Huo WS; Chen W; Tang C; Zhao L; Bai X
Medicine (Baltimore); 2022 Mar; 101(10):e29038. PubMed ID: 35451413
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety Profiles of Vernakalant for Cardioversion of Acute-onset Atrial Fibrillation: A Systematic Review and Meta-analysis.
Yu C; Li J; Zhao C; Guan Y; Wu D; Sun B; Wang X
Clin Ther; 2023 Mar; 45(3):218-231. PubMed ID: 36828756
[TBL] [Abstract][Full Text] [Related]
3. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.
McIntyre WF; Healey JS; Bhatnagar AK; Wang P; Gordon JA; Baranchuk A; Deif B; Whitlock RP; Belley-Côté ÉP
Europace; 2019 Aug; 21(8):1159-1166. PubMed ID: 31292622
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
Ma W; Guo X; Wang Q; Sun G; Wang J
J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Bash LD; Buono JL; Davies GM; Martin A; Fahrbach K; Phatak H; Avetisyan R; Mwamburi M
Cardiovasc Drugs Ther; 2012 Apr; 26(2):167-79. PubMed ID: 22418856
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
Akel T; Lafferty J
Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
[TBL] [Abstract][Full Text] [Related]
10. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
[TBL] [Abstract][Full Text] [Related]
11. [Vernakalant for the conversion of atrial fibrillation of recent onset].
Seoane L; Baranchuk A; Conde D
Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis.
Shi S; Jia Q; Shi J; Shi S; Yuan G; Hu Y
Medicine (Baltimore); 2020 Sep; 99(38):e22368. PubMed ID: 32957413
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine in the prevention and treatment of atrial fibrillation: A protocol for meta-analysis.
Yuan C; Luo W; Ren X; Ya M; Yan W; Hui Q
Medicine (Baltimore); 2021 Apr; 100(16):e25437. PubMed ID: 33879675
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
16. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
Stoneman P; Gilligan P; Mahon P; Sheahan R
Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
18. Vernakalant for the conversion of atrial fibrillation: the new kid on the block?
Conde D; Baranchuk A
Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):299-302. PubMed ID: 24738652
[TBL] [Abstract][Full Text] [Related]
19. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
20. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
